Onesource Specialty Pharma Limited — Q4 FY25 earnings call

Call held 6 May 2025

Management summary

OneSource delivered a transformative FY25, characterized by a 30% revenue jump and a doubling of EBITDA. The company is successfully pivoting toward high-value Drug Device Combinations (DDC), with 50 projects currently in the pipeline. While FY26 is signaled as a 'transition year' due to the timing of patent expiries for Semaglutide, management remains highly confident in achieving its $400 million revenue target by FY28.

Highlights

  • Full year FY25 revenue exceeded ₹1,445 crores, representing 30% YoY growth.

  • FY25 EBITDA reached ₹466.5 crores, more than doubling from FY24 levels.

  • Q4 FY25 EBITDA margin stood at a robust 43%, driven by high-margin Drug Device Combination (DDC) projects.

  • Management reaffirmed FY28 guidance of $400 million revenue with 38-40% EBITDA margins.

  • The company added 15 new customers in FY25, bringing the total logo count to over 70.

  • Net debt was significantly reduced to ₹4,707 million, with a target to be net debt-free in 2-3 years.

  • Capacity expansion is on track to reach 90 million units by December 2025 from the current 40 million.

Key financials

  1. Revenue 14,449 Mn +30%YoY
  2. Operating EBITDA 4,665 Mn +100%YoY
  3. Adjusted PAT 936 Mn
  4. EBITDA Margin 43%
  5. EPS ₹21.4
  6. ROCE 22.9%

What they filed

Q1 FY27: revenue up 37.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue334 393 426 327 376 +13%290 −26%428 +0%449 +37%
EBITDA77 142 183 88 106 +38%17 −88%92 −50%123 +40%
Net profit-42 -69 98 0 10 +124%-89 −29%5 −95%25
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • Total Revenue Revenue · FY28 · High confidence $400 million
    We continue to maintain our near-term outlook for FY '28 for a $400 million revenue top line.

    — Arun Kumar, Founder

Margin

  • EBITDA Margin Margin · FY28 · High confidence 38-40%
    with a significant EBITDA in the 38% to 40% range as has been previously guided organically.

    — Arun Kumar, Founder

Capacity

  • Rated Capacity Capacity · by December 2025 · High confidence 90 million

    From 40 million today

    we have increasing capacities from our 40 million rated capacity to a little over 90 million as early as December.

    — Arun Kumar, Founder

Debt

  • Net Debt Debt · next 2 to 3 years · Medium confidence Debt Free
    We, like we earlier mentioned, we aim to be debt free, net debt free in the next 2 to 3 years.

    — Anurag Bhagania, CFO

Capex

  • Capacity Expansion Investment Capex · next couple of years · High confidence $100 million
    will continue to invest over about $100 million over the next couple of years.

    — Anurag Bhagania, CFO

Risks & concerns

  • FY26 Transition Year Lumpiness

    medium

    Bulk of revenue growth from DDC commercial sales will only start in Q4 FY26 due to patent expiry timelines, leading to a 'tepid' H1 FY26.

    Management acknowledged

  • US FDA Observations

    medium

    One site received 4 observations (Form 483) on March 29; management claims they are 'norm' and already responded to.

    Analyst downplayed

  • Competition from Oral Formulations

    low

    Management believes injectables will remain preferred for efficacy and lower 'pill burden' (once-a-week vs daily).

    Analyst downplayed

Areas of evasion (2)

  • Specific revenue breakdown for the DDC segment
  • Exact number of planned commercial launches in FY26

Q&A highlights

2 direct
DDC Revenue Contribution Partial
we are not specifically giving DDC number. But I think we have very clearly mentioned that... we are close to about 50 DDC projects.

Investors are keen to understand the exact margin profile of the DDC segment, which management is keeping aggregated for now.

Asked by Amey, JM Financial

Market Potential in Canada and Brazil Direct
we see the markets really taking their true potential, which could be anywhere, you know, between 10 to 12 times in case of Brazil... Or maybe about 4 to 5 times in case of Canada.

Highlights the massive volume expansion expected as Semaglutide generics enter under-served markets.

Asked by Madhav, Fidelity Investments

Risk from Oral GLP-1 Drugs Direct
even Lilly has very clearly mentioned that they expect the peak share of their oral product to be no more than 25% of the total anti-obesity market.

Management addresses the primary long-term threat to their injectable DDC business model by citing innovator market share projections.

Asked by Umang Ghada, Avener Capital

2 min read 5 chapters

Detailed narrative

Record Financial Performance in FY25

OneSource Specialty Pharma reported a stellar FY25 with revenues crossing ₹14,449 million, a 30% increase YoY. The operating EBITDA grew by 79% in Q4 alone, reaching ₹1,825 million, while the full-year EBITDA of ₹4,665 million was more than double the previous year. This growth was underpinned by strong execution of contracts and the onboarding of 15 new customers, bringing the total to over 70 logos.

FY26 as a Strategic Transition Year

Management explicitly labeled FY26 as a transition year, cautioning that H1 FY26 might appear 'tepid' compared to a strong H2. This is primarily due to the timing of Semaglutide patent expiries, which are concentrated in March 2026. Consequently, commercial supplies for DDC products are expected to ramp up significantly only in Q4 FY26, mirroring the 'lumpy' performance seen in FY25.

Dominance in Drug-Device Combinations (DDC)

The DDC segment is the primary growth engine, with approximately 50 projects currently in various stages of execution. Management highlighted that they have 20+ customers specifically for DDC, and the Q4 EBITDA margin of 43% reflects the high-value nature of these Master Service Agreement (MSA) executions. They are currently focusing on existing customers to avoid capacity clashes, given the high demand for GLP-1 and other self-administered injectables.

Aggressive Capacity Expansion and Capex

To meet the anticipated surge in demand for GLP-1 generics, OneSource is expanding its rated capacity from 40 million units to over 90 million units by December 2025. The company plans to invest approximately $100 million in capex over the next two years. Furthermore, management teased a long-term plan to reach 220 million units of capacity, primarily located in India but with potential for inorganic global expansion.

De-leveraging and Balance Sheet Strength

The company made significant strides in treasury operations, reducing net debt to ₹4,707 million by the end of the quarter. CFO Anurag Bhagania noted that high-cost debt was prepaid, reducing interest costs by 20% quarter-over-quarter. The company aims to maintain a debt-to-EBITDA ratio below 1.5x and intends to be completely net debt-free within the next 2 to 3 years.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls